CurrentBlue Cross Blue Shield - MassachusettsPolicy 610

Radiation therapy for choroidal neovascularization (epiretinal brachytherapy, proton beam, stereotactic radiotherapy)

This policy addresses coverage and prior authorization requirements for intraocular and external radiation treatments (brachytherapy, proton beam, stereotactic radiotherapy) used to treat choroidal neovascularization associated with age-related macular degeneration for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyRadiation therapy for choroidal neovascularization (epiretinal brachytherapy, proton beam, stereotactic radiotherapy)

Policy CodePolicy 610

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient procedures described in this policy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3radiation modalities reviewed

RCTsRCTs referenced

Prior authinpatient requirement

Not coveredoutpatient stance

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational/Not Covered

Covered when ALL of the following are met:

Medicare statement: Intraocular placement of a radiation source (brachytherapy) for the treatment of choroidal neovascularization is INVESTIGATIONAL for Medicare HMO and Medicare PPO members.

Medicare-specific investigational determination.

Proton beam therapy for the treatment of choroidal neovascularization is INVESTIGATIONAL.

Stereotactic radiotherapy for the treatment of choroidal neovascularization is INVESTIGATIONAL.

Evidence summary: Current evidence is insufficient to demonstrate improvement in net health outcome for brachytherapy, proton beam therapy, or stereotactic radiotherapy for choroidal neovascularization due to age-related macular degeneration; randomized trials did not show visual acuity benefit and brachytherapy was associated with higher adverse events.

Summary of clinical trial outcomes and evidence insufficiency.

Outpatient epiretinal/intraocular radiation procedures (including brachytherapy, proton beam therapy, and stereotactic radiotherapy) are designated as not a covered service for multiple product lines when performed in the outpatient setting. This includes Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO (BlueSM), and Medicare PPO (BlueSM) product lines; performing these procedures outpatient may lead to non-coverage or claim denial. Precertification/preauthorization remains required for inpatient services described in this policy.

The available evidence is insufficient to determine an improvement in net health outcome for intraocular radiation therapies used to treat choroidal neovascularization due to age-related macular degeneration. For brachytherapy, two randomized controlled trials and systematic reviews found brachytherapy did not achieve noninferiority for visual acuity and was associated with a higher rate of adverse events. For proton beam therapy, a randomized sham-controlled trial (with recruitment halted for ethical concerns) and a pilot study did not demonstrate statistically significant stabilization of visual acuity. For stereotactic radiotherapy, an RCT showed fewer anti-VEGF injections at 12 and 24 months but no significant differences in visual acuity compared with controls. Across these modalities, evidence does not establish net clinical benefit.

Provider Actions and Billing

Prior Authorization

Prior Authorization Required

Precertification/preauthorization is required for inpatient services described in this policy. Providers must obtain prior authorization before performing these inpatient procedures to avoid claim denials or payment delays.

Preauthorization required for all products when performed inpatient
Obtain prior authorization before scheduling inpatient procedures

Denial Risk

Outpatient Noncoverage Risk

Outpatient procedures described in this policy are frequently recorded as "not a covered service" for multiple commercial and Medicare product lines. Verify member benefits and coverage prior to providing outpatient services; when outpatient services are not covered, claims will be denied.

Commercial Managed Care (HMO and POS): Outpatient = Not a covered service
Commercial PPO and Indemnity: Outpatient = Not a covered service
Medicare HMO: Outpatient = Not a covered service
Medicare PPO: Outpatient = Not a covered service

Billing Rule

Billing and Coding Requirements

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, and include applicable modifiers. Accurate coding and documentation support authorization decisions and correct claims processing.

Report services with current CPT/HCPCS, Revenue, and ICD-10 diagnosis codes
Include appropriate modifiers where applicable

Note

Provider Treatment Recommendation

Standard management for neovascular age-related macular degeneration uses intravitreal anti-VEGF agents (for example, pegaptanib, ranibizumab, bevacizumab, aflibercept). Alternative treatments such as intraocular radiation (brachytherapy, proton beam, stereotactic radiotherapy) are investigational or under investigation and are not considered standard of care.

Standard therapy: Intravitreal anti-VEGF injections (pegaptanib, ranibizumab, bevacizumab, aflibercept)
Radiation therapies (brachytherapy, proton beam, stereotactic radiotherapy) are investigational alternatives

Background

Age-related macular degeneration (AMD) is a leading cause of legal blindness in people older than age 60. The neovascular or "wet" form involves choroidal neovascularization (CNV), which carries a higher risk of severe vision loss. Standard clinical management of neovascular AMD relies on repeated intravitreal anti–vascular endothelial growth factor (anti-VEGF) injections. Intraocular and external radiation approaches (epiretinal brachytherapy, proton beam therapy, stereotactic radiotherapy) have been investigated as alternative or adjunctive treatments to reduce lesion activity or injection frequency, but clinical trials to date have not demonstrated consistent visual acuity benefit.

Definitions

Epiretinal brachytherapy — definition and delivery description

TermEpiretinal brachytherapy (NeoVista Epi-Rad90)

MethodHandheld, pipette-like intraocular delivery via standard vitrectomy with a cannula tip positioned over the CNV lesion

Radiation source and doseStrontium-90 beta-particle source delivering a single peak dose of 24 Gray

Target geometryDesigned to treat a target ~3 mm in depth and up to 5.4 mm in diameter

Exposure profileFocused, single-session delivery with minimal expected radiation exposure outside the target; dose believed below toxicity threshold for retina and optic nerve

Proton beam therapy — definition and Bragg peak characteristic

TermProton beam therapy

DefinitionExternal charged-particle radiotherapy using protons or helium ions to target tissues

Physical characteristicDeposits ionizing energy at a specific depth (Bragg peak) with less scatter than photon radiotherapy

Proposed advantageAbility to deliver higher radiation doses to the target with reduced dose to adjacent normal tissue

Stereotactic radiotherapy — definition and delivery approach

TermStereotactic radiotherapy

Delivery approachNonsurgical, robotically controlled external-beam technique delivered in an office setting

Beam geometryMultiple overlapping radiation beams are directed through the inferior sclera to converge at the macula

Intended useExternal radiotherapy technique proposed to treat choroidal neovascularization by focusing beams on the macula while sparing surrounding tissues